This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schmidt, W. K. Search for Related Content PubMed Articles by Schmidt, W. K. Social Bookmarking                         What's this?

Drug Development for Disorders of the Nervous System: Challenge and Opportunity at the Pharmaceutical-Biotech-Academic Interface

NorthStar Research & Development, Ltd. Newark, Delaware

Drug development for epilepsy, drug abuse, amyotrophic lateral sclerosis, narcolepsy, and other less profitable neurological and psychiatric diseases has often had an uncertain past without the innovation and investment of major pharmaceutical company sponsors. A change has occurred in recent years as newer molecular techniques have made drug discovery accessible to both larger and smaller biopharmaceutical companies, but even more rapid innovation is possible through an alignment of interests by industry, academic, and government collaborators. Several newer medications for epilepsy and drug addiction have emerged only because of cooperative interactions between academic, pharmaceutical company, and government investigators. This sets the stage for even more rapid innovation for underrepresented diseases in the future. NEUROSCIENTIST 4:9-13, 1998

Key Words: KEY WORDS Drug development • Orphan drug • Epilepsy • Drug abuse

The Neuroscientist, Vol. 4, No. 1, 9-13 (1998)
DOI: 10.1177/107385849800400108


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?